Back to results
US 2022/0009999 A1Published application
Anti-vegf protein compositions and methods for producing the same
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAndrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li
Life of this patent
Estimating the term…
Abstract
The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
Claims30
A method of producing aflibercept, comprising:
- (a) binding aflibercept from a clarified harvest cultured in a chemically defined medium (CDM) to a Protein A resin, wherein said aflibercept includes variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine, phenylalanine, tyrosine and a combination thereof;
- (b) eluting said aflibercept of step (a) forming an affinity eluate, wherein said eluate has a first color,
- wherein said first color is no more yellow-brown than European Color Standard BY1;
- (c) subjecting said eluate comprising aflibercept to anion exchange chromatography (AEX) column;
- and
- (d) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color,
- wherein said second color has a European Color Standard BY2 or greater, and wherein said first color of said affinity eluate is a more intense yellow brown color than said second color of said flowthrough fraction when said affinity eluate and flowthrough fraction protein concentrations are normalized.
4 more elements
A method of producing aflibercept, comprising:
- a. binding aflibercept from a clarified harvest cultured in a chemically defined medium (CDM) to a Protein A resin, wherein said aflibercept includes oxidized species of aflibercept that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine, phenylalanine, tyrosine and a combination thereof;
- b. eluting said aflibercept of step (a) forming an affinity eluate, wherein said eluate comprises oxidized species of aflibercept;
- c. subjecting said eluted aflibercept to anion exchange (AEX) chromatography column;
- and
- d. collecting a flowthrough fraction, wherein the percent of oxidized species of aflibercept in said affinity eluate is greater than the percent of oxidized species of aflibercept in said flowthrough fraction when the concentrations of protein in said eluate and flowthrough fraction are normalized, and
- wherein said oxidized species of aflibercept is measured by subjecting said affinity eluate and said flowthrough fractions to digestion, followed by their analysis using reverse-phase ultra-performance chromatography (UPLC), detection at wavelengths of 280 nm, 320 nm and 350 nm and mass spectrometry analysis using a first mobile phase of 0.1% v/v formic acid in water and a second mobile phase of 0.1% v/v formic acid in acetonitrile
3 more elements
Dependencies are inferred from the claim text.